Saturday 17 October 2026
Export TYRA’s income statement to Excel — free account
Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.52
0.52
−2.73%
Follow TYRA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 | — |
Net Debt/EBITDA |
1.94 | 3.29 | 2.56 | 4.28 | 11.56 | 1.65 | (0.05) | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 47.92% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.05) | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.79 | 0.81 | 0.73 | 0.91 | 0.90 | 0.83 | 0.64 | — |
Capex/Depreciation |
(0.26) | (1.28) | (2.16) | (1.89) | (4.61) | (6.64) | 0.00 | — |
Interest Coverage |
— | — | — | — | — | — | (6,244.00) | — |
| (39.83%) | (31.60%) | (29.92%) | (19.77%) | (18.25%) | 101.59% | 44.24% | — | |
| (37.13%) | (29.34%) | (28.10%) | (19.31%) | (16.30%) | (112.90%) | (1,539.77%) | — | |
ROIC |
(2,614.25%) | (3,807.64%) | (6,300.84%) | (556.67%) | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(48.24%) | (25.85%) | (34.92%) | (21.90%) | (8.72%) | (68.05%) | 85.54% | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — |
Free Cash Flow per Share |
(1.60) | (1.23) | (1.19) | (1.21) | (1.77) | (5.24) | (0.06) | — |
Cash per Share |
4.30 | 5.97 | 4.76 | 6.00 | 21.93 | 9.87 | 0.00 | — |
Shareholders Equity per Share |
4.35 | 6.00 | 4.78 | 6.16 | 21.90 | (8.84) | (0.11) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
4.35 | 6.00 | 4.78 | 6.16 | 21.90 | (8.84) | (0.11) | — |
Free Cash Flow |
(95.28) | (70.44) | (50.91) | (50.84) | (24.39) | (8.07) | (2.62) | — |
Working Capital |
247.36 | 332.87 | 196.34 | 251.59 | 300.44 | 13.42 | (5.03) | — |
Capital Expenditures |
(0.14) | (0.66) | (0.77) | (0.56) | (0.64) | (0.31) | (0.02) | — |
Net Current Asset Value |
242.02 | 327.06 | 190.08 | 248.94 | 299.09 | (14.37) | (5.14) | — |
| Other line items | ||||||||
Quick Ratio |
14.15 | 23.40 | 13.27 | 44.06 | 83.57 | 8.19 | 0.02 | — |
Depreciation/Fixed assets |
0.42 | 0.31 | 0.22 | 0.27 | 0.14 | 0.16 | 0.03 | — |
Cash ROIC |
(18.50%) | (10.29%) | (12.49%) | (9.99%) | (4.04%) | (509.14%) | 59.77% | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14,919.38 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(1.60) | (1.22) | (1.17) | (1.20) | (1.72) | (5.03) | (0.06) | — |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.01) | (0.05) | (0.20) | 0.00 | — |
Average Payables |
0.88 | 2.63 | 2.90 | 0.87 | 0.63 | 0.50 | 0.50 | — |
Average Assets |
323.08 | 294.71 | 246.02 | 286.44 | 161.36 | 8.27 | 0.26 | — |
Average Common Equity |
301.16 | 273.71 | 231.05 | 279.78 | 144.05 | (9.19) | (9.19) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Columns are period end dates